As #oncologytrainees prepare for their first #patientencounter, the #SPIKES protocol is often a good starting point. What advise do you have for #trainees when #deliveringbadnews? @marklewismd @NarjustDumaMD @GlopesMd @mtmdphd @VPrasadMDMPH @DevikaDasMD @MayoHemeOnc #HOFellowLife

LOOK- same few antigens every time! Everyone crowding onto validated biology while the hard targets wait. New ideas are hard, but that's where patients need us to go ;)

Agree, lung cancer ADC/BsAb pipelines look the same. We mapped 47 active trials (@ClinLungCancer): • BsAbs ~70% / ADCs ~30% • Top BsAb: EGFR×c-MET (~28%) • Top ADC: TROP2 (~33%), HER2 (~20%) Same few antigens. More me-too than novel. doi.org/10.1016/j.cllc.2024.…

KEYNOTE-867 ph3 (@JCO_ASCO): SBRT ± pembro, inoperable stage I–II NSCLC (n=448) ➡️ mEFS 31.2 vs 28.3 mo, HR 0.92 ➡️ G3–5 TRAEs 20.4 vs 3.7% ➡️ 5 G5 TRAEs, all pembro; stopped early Why is SBRT alone so hard to beat? doi.org/10.1200/JCO-26-00404 @LungCancerRx @OncoAlert @oncodaily

Completely agree with @DrJNaidoo, @teekayowo for @ASCO President Elect!!!

DeLLphi-305🚨 A 0.42 hazard ratio for death in extensive-stage small-cell lung cancer. In a disease where we’ve celebrated gains of two to three months, this is a different level. 🫁 Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer nejm.org/doi/full/10.1056/NE… @MP_3855, @ADesaiMD 📊 In the open-label phase 3 DeLLphi-305 trial, 563 patients with extensive-stage SCLC without progression after first-line chemoimmunotherapy were randomized to tarlatamab plus durvalumab or durvalumab alone as maintenance. The median overall survival was 21.1 versus 12.7 months (HR 0.42), and the median PFS 7.4 versus 1.9 months (HR 0.34). Grade ≥3 adverse events occurred in 46.8% versus 40.6%; cytokine release syndrome, mostly grade 1–2, affected nearly half of tarlatamab-treated patients. #LungCancer Pinging our faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers

Agentic #AI irAE chart review, 1 health system (@NatureCancer) ➡️ F1 0.92 detection, 0.66 CTCAE grade ➡️ Prospective silent run: F1 0.72–0.79 ➡️ Crossover RCT: median 428 vs 242 s/note Who verifies AI grade? Where does liability sit? nature.com/articles/s43018-0… @OncoAlert

Friends, 🙏 consider voting for @RManochakian who has been a phenomenal educator, clinician and patient advocate! I remember meeting him when I came to @MayoCancerCare FL and his warm and kind personality stayed with me since! @ASCO will be lucky to have him join!

AI-INFOCARE RCT (@NEJM_AI): checked AI lay summaries before clinic (n=300) ➡️ Patient-rated interaction 4.42 vs 4.25, P=0.005 ➡️ Median visit 25 vs 33 min ➡️ Physicians rated own autonomy support lower Shorter visit, better visit? @LungCancerRx @OncoAlert @oncodaily

R-ALPS ph3 (@JAMAOnc): post-CRT stage III NSCLC (n=553) ➡️ PFS: benmelstobart+anlotinib 15.1, benmelstobart 9.7, placebo 4.2 mo ➡️ Combo vs IO alone: HR 0.82, P=.12 ➡️ G5 TRAEs 7.2% vs 1.4% Any room left for anti-VEGF consolidation? I think no @LungCancerRx @OncoAlert @oncodaily

@myESMO 2026: Most discussed lung cancer trials by influencer posts on 𝕏. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #LungCancer #SCLC #esSCLC #NSCLC #LCSM #ClinicalOncology | @HHorinouchi | @GlopesMd | @ADesaiMD | @DrRiyazShah | @Latinamd | @Alfdoc2 | @FernandoOnco | @Tony_Calles | @M_Torasawa

FDA-cleared PE AI, real world vs clearance (@NaturePortfolio npj Digit Med, 17 sites) ➡️ CTPA sensitivity 86.8% vs 94.9% in 510(k) ➡️ Incidental PE 73.5% vs 89.7% ➡️ Subsegmental 72.9%; non-acute 65.3% ❓Who should check AI tools after go-live, and how often?

PEARLS/KN-091 final, #ESMO26: adjuvant pembro, resected IB–IIIA NSCLC (n=1,177) ➡️ DFS 58.7 vs 43.3 mo, HR 0.85 ➡️ OS HR 0.98 (0.81–1.18); 6-yr 68.5% vs 66.4% ➡️ OS read time-triggered before planned deaths Is DFS enough in adjuvant IO? @LungCancerRx @OncoAlert @oncodaily

PERSEE ph3 #ESMO26: pembro ± chemo, 1L NSCLC PD-L1≥50% (n=321) ➡️ PFS 16.1 vs 6.9 mo, HR 0.56 ➡️ ORR 77.5% vs 50.3%; early PD 5.8% vs 26.5% ➡️ OS 50.2 vs 29.9 mo, HR 0.77, not powered ➡️ G≥3 TRAEs 54% vs 19% Who gets pembro mono now? @LungCancerRx @OncoAlert @oncodaily

MGC026 (B7-H3 ADC) phase 1 at #ESMO26 @myESMO ➡️ Escalation ≥6 mg/kg: cORR 29% (5/17), mDoR 10.2 mo ➡️ SCCHN 7.5 mg/kg: best ORR 27% (6/22) ➡️ No ILD/pneumonitis/ocular tox (N=85) Interesting to see if development plans for SCLC ? @LungCancerRx @OncoAlert @oncodaily

Anthropic update: not just molecule design. ➡️ Bottlenecks distributed; next = human trials ➡️ @BMS used Claude for early study plans + PoS Phase 1 Q: does AI PoS weight enrollability + biomarkers like we do bedside? @OncoAlert @oncodaily

AI clinical Q&A at scale! @JAMA_current ➡️ 952,008 US clinicians, 271M queries @OpenEvidence ➡️ Onc/heme use ratio 2.00 (top) ➡️ Treatment/mgmt 33.1% vs diagnosis 13.9% Retrieval is now, actionability in care, outcomes & trials are the future! @oncodaily @AIoncology

Antigen-directed phase 1 ADCs at #ESMO26 ➡️ ABBV-706 (SEZ6), R/R SCLC: ORR 56% (n=41), mOS 12.4 mo ➡️ BG-C477 (CEA), NSCLC: ORR 60.0% CEA-high (n=25) vs 37.2% overall (N=43) Still valuable to select on IHC? Interesting to see CEACAM5 comeback! @LungCancerRx @OncoAlert @oncodaily

SANOVO #ESMO26: osi ± savolitinib, 1L EGFRm MET-overexpressed NSCLC (China) ➡️ mPFS IHC3+ 24.8 vs 11.1 mo, HR 0.45 ➡️ mPFS ITT 24.9 vs 13.8 mo, HR 0.56 ➡️ mOS 44.5 vs 34.9 mo, HR 0.48 ➡️ 3-yr OS 67.4 vs 47.4% Test MET IHC at EGFRm diagnosis? @LungCancerRx @OncoAlert @oncodaily

HERON-Lung01 #ESMO26: HER3 ADC ruzaltatug rezetecan vs platinum-pem, EGFRm NSCLC post-TKI ➡️ mPFS 8.3 vs 5.4 mo, HR 0.47 ➡️ ORR 60.0 vs 34.3% ➡️ OS HR 0.70, immature ➡️ ILD 2.4% Two HER3-targeting ADCs, one session. How do we sequence them? @LungCancerRx @OncoAlert @oncodaily

ROSETTA Lung-107 #ESMO26: pumitamig (PD-L1×VEGF) + docetaxel post chemo-IO, single-arm Ph2 ➡️ cORR 36.7% (n=30) ➡️ DCR 90.0% ➡️ mPFS 6.9 mo; f/u 12.2 wk ➡️ G≥3 pumitamig TRAEs 18.0% Early signal after chemo-IO. Randomized data next? @LungCancerRx @OncoAlert @oncodaily